FDA to expedite review of Takeda's ulcerative colitis drug

The FDA granted priority-review status to Takeda Pharmaceutical's application to market vedolizumab for the treatment of patients with moderately to severely active ulcerative colitis. The designation will shorten the drug review period from one year to eight months.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Actuary
NTA Life
Addison, TX
Manager of Payer Relations
Pharmacy Quality Solutions, Inc.
Raleigh/Durham, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN